PDCD1 and pachyonychia congenita: (13) also demonstrated disappointing results in the phase II clinical study, reporting no significant difference in survival benefit between sintilimab (PD-1 antibody) plus the modified FOLFIRINOX arm and modified FOLFIRINOX arm alone among 55 patients with advanced PC.